Acceso usuarios
Pedro Borges de Souza, Taiane de Azevedo Cardoso, Thaise Campos Mondin, Luciano Dias de Mattos Souza, Ricardo Azevedo da Silva, Andressa Schneider Lobato, Miriam Haj Omar, Jean Pierre Oses, Carolina David Wiener, Karen Jansen, Fernanda Pedrotti Moreira
ackground and Objectives: Major Depressive Disorder (MDD) is characterized by cognitive dys- function and neurotropic and inflammatory factors linked to its pathophysiology and cognitive impairment. This study aims to identify the prodromal serum biomarkers correlated to cognitive impairment in individuals diagnosed with MDD, including variation between sexes.
Methods: This study is part of a larger two-stage research. The initial stage involved the sample of participants aged between 18 and 60 years old, diagnosed with MDD. The second phase took place three years later. The baseline assessments included a biomarker blood test (BDNF, GDNF, NGF, IL-6 and TNF-a). Follow-up assessments used the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) for subjective cognition and the number-letter sequence of the Wechsler Adult Intelligence Scale (WAIS-III) for objective cognition.
Results: The sample consisted of 155 subjects, 30 males and 125 females. In the sex-stratified sample, a correlation was found between COBRA and GDNF biomarkers in males (r= -0.339;
p = 0.039). When COBRA was applied as a dependent variable in the multiple linear regression, the overall model was significant (Z (9, 50) = 2.611, p = 0.032; adjusted R2 = 0.620), with the highest impact on sex (b = 0.442, p = 0.003, padjFDR = 0.019), symptom severity (b = 0.605, p < 0.001, padjFDR = 0.013) and GDNF levels (b = -0.414, p = 0.005, p adjFDR = 0.021).
Conclusions: Our results suggest that GDNF might be a prodromal biomarker for the early detec- tion of subjective cognitive complaints only when targeting males with MDD.
© 2024 Sociedad Española de Psiquiatría y Salud Mental. Published by Elsevier España, S.L.U. All rights reserved.
